ระบบนําส่งนีโอโซมในทางเภสัชกรรม
Article Sidebar
Main Article Content
บทคัดย่อ
นีโอโซมเป็นถุงอนุภาคมีผนังเป็นชั้น ที่เกิดจากการพองตัวของสารลดแรงตึงผิวชนิดไม่มีประจุเพียงอย่างเดียวหรือใช้ร่วมกับไขมัน เช่น คอเลสเตอรอล เป็นต้น แรกเริ่มมีรายงานการใช้นีโอโซมในอุตสาหกรรมเครื่องสำอาง ปัจจุบันระบบอนุภาคชนิดนี้สามารถนำมาใช้เป็นระบบนำส่งสารสำคัญที่มีคุณสมบัติชอบหรือไม่ชอบไขมันได้เช่นเดียวกับลิโพโซม นีโอโซมมีข้อดีที่เหนือกว่าลิโพโซมคือมีความคงตัวทางเคมีดีกว่า เนื่องจากลิโพโซมมีฟอสโฟลิพิดที่สามารถสลายตัวได้ง่าย นีโอโซมจึงเป็นตัวเลือกที่ดีของระบบนำส่งยา ที่มีความเป็นพิษต่ำสามารถปรับดัชนีในการรักษาให้จํากัดและควบคุมการออกฤทธิ์เฉพาะเซลล์เป้าหมายได้ บทความวิจารณ์มีเนื้อหาเกี่ยวกับภาพรวมของปัจจัยที่มีผลต่อการเกิดนีโอโซม เทคนิคการเตรียมนีโอโซม การประเมินลักษณะของนีโอโซมและการประยุกต์ใช้นีโอโซมในทางเภสัชกรรม
Article Details
กรณีที่ใช้บางส่วนจากผลงานของผู้อื่น ผู้นิพนธ์ต้อง ยืนยันว่าได้รับการอนุญาต (permission) ให้ใช้ผลงานบางส่วนจากผู้นิพนธ์ต้นฉบับ (Original author) เรียบร้อยแล้ว และต้องแนบเอกสารหลักฐาน ว่าได้รับการอนุญาต (permission) ประกอบมาด้วย
เอกสารอ้างอิง
Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008; 357(1-2): 189-198.
Aggarwal D, Garg A, Kaur IP. Development of a topical niosomal preparation of acetazolamide: Preparation and evaluation. J Pharm Pharmacol2004; 56: 1509-1517.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system.Int J Pharm2005; 290: 155-159.
Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of nonionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int J Pharm 2000; 201(1): 7-14.
Arunothayanun P, Uchegbu IF, Florence AT.Osmotic behaviour of polyhedral non-ionic surfactant vesicles (niosomes). J Pharm Pharmacol1999; 51(6): 651-7.
Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol1985; 37: 237-242.
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes- Non-ionic surfactant vesicles. J Pharm Pharmacol 1985; 37: 863-868.
Baillie AJ, Coombs GH, Dolan TF. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stribogluconate, J Pharm Pharmacol 1986; 38: 502-505.
Balasubramaniam A, Kumar VA, Pillai KS. Formulation and in vivo evaluation of niosome encapsulated daunorubicin hydrochloride. Drug Dev and Ind Pharm 2002; 28: 1181-1193.
Beugin-Deroo S, Ollivon M, Lesieur S. Bilayer stability and impermeability of nonionic surfactant vesicles sterically stabilized by PEG-cholesterol conjugates. J Colloid Interface Sci 1998; 202: 324-333.
Bhaskaran S, Lakshmi PK. Comparative evaluation of niosome formulations prepared by different techniques. Acta Pharm Sci 2009; 51: 27-32.
Bouwstra JA, VanHal DA, Hofland HEJ. Preparation and characterization of nonionic surfactant vesicles.Colloid Surf A Phy Eng Asp 1997; 123-124: 71-80.
Brewer JM, Roberts CW, Conacher M, McColl J, Blarney BA, Alexander J. An adjuvant formulation that preferentially induces T helper cell type 1 cytokine and CD8+cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production. Vaccine Res 1996; 5: 77-89.
Buckton GH, editor. Interfacial phenomena in Drug Delivery and Targeting. Switzerland: Academic Publishers; 1995. 154-155.
Cable C. An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. [PhD thesis] Pharmaceutical Sciences, University of Strathclyde. Glasgow: 1989.
Carafa M, Santucci E, Lucania G. Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm2002; 231: 21-32.
Cevc G, Schatzlein A, Blume G. Transdermal drug carriers-basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides. J Control Rel 1995; 36: 3-16.
Cevc G, Blume G, Schatzlein A, Gebauer D, Paul A. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Del Rev 1996; 18: 349-378.
Chandraprakash KS, Udupa N, Umadevi P, Pillai GK. Effect of macrophage activation on plasma disposition of niosomal 3H-Methotrexate in sarcoma-180 bearing mice. J Drug Target1993; 1(2): 143-145.
Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. J Pharm Pharmacol 1989; 41: 6.
Donatella P, Rita M, Antonio R, et al.,In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices, 2007; 9: 421-433.
Dufes C, Gaillard F, Uchegbu IF, Schatzlein AG, Olivier JC, and Muller JM. Glucosetargeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 2004; 285: 77-85.
Florence AT, Arunothayanun P, Kiri S, Bernard MS, Uchegbu IF. Some Theological properties of nonionic surfactant vesicles and the determination of surface hydration. J Phys Chem B 1999; 103: 1995-2000.
Gopinath D, Ravi D, Rao BR, Apte SS, Renuka D, Rambhau D. Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and application. Int J Pharm 2004; 271(1-2): 95-113
Handjani-vila RM, Ribier A, Rondot B, Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J cosmet Sci1979; 1(5): 303-314.
Hassan Y, Brewer JM, Alexander J, Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMS or NISV deliverysystems. Vaccine 1996; 14: 1581-1589.
Hilgers LA, Zigtermann GJWJ, Snippe H. Immunomodulating properties of amphiphilic agents. In: Kammuller ME, Bioksma N, Sienen W, editors. Autoimmunity and Toxicology, Amsterdam: Elsevier; 1989. 294-306.
Hofland HEJ, Geest VR, Bodde HE, Junginger E, Bouwstra JA. Estradiol Permeation from Nonionic Surfactant Vesicles Through Human Stratum Corneum in Vitro. Pharm Res, 1995; 11: 659-664.
Honeywell-Nguyen PL, Bouwstra JA. The in vitrotransport of pergolide from surfactant-based elastic vesicles through human skin: A suggested mechanism of action. J Control Rel 2003; 86: 145-156.
Hunter CA, Dolan TF, Coombs GH, Baillie AJ. Vasicular systems (niosomes and liposomes) in experimental murine visceral leishmaniasis for delivery of sodium stibogluconate. J Pharm Pharmocol 1988; 40: 161-165.
Kaneshina S, Shibata O, Nakamura M. The effect of pressure on the mutual solubility of a nonionic surfactant water system.Bull Chem SocJapan1982; 55: 951-952.
Khandare JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. The Eastern Pharmacist 1994; 37: 61-64.
Kumar A, Pal J, Jaiswal A, Singh V. Review on niosomes as novel drug delivery system.Int Res J Pharm2011; 2(5): 61-65.
Lakshami PK, Gayathri SD, Bhaskaran S, Sacchdanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies Indian J Dermatol Venerol Leprol, 2007; 73: 157-161.
Luciani A, Olivier J, Clement OG, Siauve N, Frija G, Cuenod C. Glucose receptor directed stealth niosomes for MR tumor detection: Preliminary studies in mice. Radiology 2002; 225: 123-123.
Luciani A, Olivier JC, Clement O, et al. Glucose-receptor MR imaging of tumors: Study in mice with PEGylated paramagnetic Niosomes. Radiology2004; 231: 135-142.
Malhotra M, Jain NK. Niosomes as Drug Carriers. Indian Drugs 1994; 31(3): 81-86.
Mohamed SE, Alia AB, Marwa MS, Amira MM. Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin.Int J Pharm Pharm Sci 2012; 4(1): 549-559.
Mokhtar M, Sammourb OA,Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 2008; 361: 104-11.
Murdan S, Gregoriadis G, Florence AT. Sorbitan monostearate/ Polysorbate20 organogels containing niosomes: a delivery vehicle for antigen. Eur J Pharm Sci 1999; 8(3): 177-186.
Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. Antiinflammatory activity of Niosome encapsulated diclofenac sodium with Tween 85 in Arthitic rats. Ind J Pharmacol 1994; 26: 46-48.
Naresh RA, Udupa N, Devi PU. Toxicity and antitumor activity of niosomal bleomycin in tumor bearing mice.Indian J Exp Biol. 1996 Aug; 34(8): 764-72.
Nasseri B, Florence AT. Microtubules formed by capillary extrusion and fusion of surfactant vesicles. Int J Pharm 2003; 266: 91-98.
Ozer AY, Hincal AA, Bouwstra JA.A novel drug delivery system nonionic surfactant vesicles. Eur J Pharm Biopharm 1991; 37: 75-79.
Perrie Y, Barralet JE, McNeil S, Vangala A. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route. Int J Pharm 2004; 284: 311.
Reddy DN, Udupa N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm 1993; 19: 843-852.
Rogerson A, Cummings J, Florence AT. Adriamycin-loaded niosomes-drug entrapment, stability and release. J Microencap 1987; 4: 321-328.
Shahiwala A, Misra A. Studies in topical application of niosomally entrapped nimesulide. J Pharma Sci 2002; 5: 220-225.
Uchegbu IF, Florence AT.Nonionic surfactant vesicles (Niosomes)-physical and pharmaceutical chemistry.Adv Coll Interf Sci 1995; 58:1-55.
Uchegbu IF, Double JA, Turton JA, Florence AT. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res 1995; 12: 1019-1024.
Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70.
Uchegbu IF, Schatzlein A, Vanlerberghe G, Morgatini N, Florence AT.Polyhedral Non-ionic Surfactant Vesicles. J Pharm Pharmacol 1997; 49(6): 606-610.
Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT.The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models.J Drug Target 1996; 3(5): 399-409.
Unezaki S, Maruyama K, Ishida O, Suginaka A, Hosoda J, Iwatsuru M. Enhanced tumour targeting and improved antitumour activity of doxorubicin by long circulating liposomes containing amphipathic poly(ethylene glycol). Int J Pharm1995; 126: 41-48.
VanHal D, VanRensen A, deVringer T, Junginger H, Bouwstra J. Diffusion of estradiol from non-ionic surfactant vesicles through human stratum corneum in vitro. STP Pharma Sci1996; 6: 72-78.
Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998; 53: 466-469.
Yasin MN, Hussain S, Malik F, et al. Preparation and characterization of chloramphenicol niosomes and comparison with chloramphenicol eye drops (0.5%w/v) in experimental conjunctivitis in albino rabbits. Pak J Pharm Sci 2012; 25(1): 117-121.
Yoshioka T, Sternberg B, Florence AT. Preparation and properties of Vesicles (Niosomes) of sorbitan monoesters (Span-20, Span-40, Span-60 and Span-80) and a Sorbitan Triester (Span-85).Int J Pharm 1994; 105:1-6.
Yoshida H, Lehr CM, Kok W, Junginger HE, Verhoef JC, Bouwistra JA. Niosomes for oral delivery of peptide drugs. J Control Rel 1992; 21: 145-153.
